Clinical trial
Sorafenib and Erlotinib in Treating Patients With Metastatic or Unresectable…
NCT00126620 · University Health Network, Toronto, Other · Completed
Key facts
| NCT number | NCT00126620 |
|---|---|
| Title | Sorafenib and Erlotinib in Treating Patients With Metastatic or Unresectable Solid Tumors |
| Official title | A Phase I Study of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib; Tarceva) in Advanced Solid Tumors |
| Lead sponsor | University Health Network, Toronto, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | erlotinib hydrochloride, sorafenib tosylate |
| Enrollment | 17 |
| Start date | Sep 1, 2005 |
| Primary completion | May 1, 2011 |
| First posted | Aug 4, 2005 |
| Last update posted | Jul 23, 2015 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: